to identify, counsel, and manage high risk patients. This study aims to identify discriminatory biomarkers in mid-trimester maternal blood for the prediction of adverse outcomes in patients with SLE. STUDY DESIGN: The study population consisted of pregnant women whose plasma was taken in mid-trimester and was available for metabolic profiling: (1) pregnant women with SLE and normal pregnancy outcome (Group 1, n¼21); (2) pregnant women with SLE with subsequent adverse pregnancy outcome (Group 2, n¼12); (3) normal pregnant women without SLE, matched for gestational age at sampling (Group 3, n¼10). Adverse pregnancy outcome was defined as one or more of the following: fetal death in utero, preeclampsia, small for gestational age (birth weight <5 th percentile), indicated preterm birth (<36 weeks), and neonatal death. Stored midtrimester maternal plasma was measured for sFlt-1/PlGF. Integrative profiles of primary metabolite and phospholipid were acquired using gas chromatography time-of-flight mass spectrometry (GC-TOF MS) and liquid chromatography Orbitrap mass spectrometry (LCOrbitrap MS). RESULTS: Among 33 women with SLE, adverse pregnancy outcome developed in 12 (36%). Metabolite profiling of mid-trimester maternal plasma samples identified 389 metabolites using GC-TOF MS and LC-Orbitrap MS. Partial least squares discriminant analysis (PLS-DA) showed clear discrimination among the profiles of SLE with normal pregnancy outcome, SLE with adverse pregnancy outcome, and normal pregnancy (Groups 1,2, and 3) [Fig 1] . Binary logistic regression modeling suggested potential metabolic biomarkers discriminating Group 1 and 2 to predict adverse pregnancy outcome in SLE. Receiver operating characteristic (ROC) analysis revealed the best predictability for adverse pregnancy outcomes with the linear combination of two metabolites (LPC 22:5 and tryptophan) with AUC of 0.944, comparable to the AUC of sFlt-1/PlGF (AUC 0.857) [Fig 2] . CONCLUSION: Metabolic biomarkers in mid-trimester maternal blood can accurately predict composite adverse pregnancy outcomes in patients with SLE. OBJECTIVE: Glucose tolerance testing for gestational diabetes (GDM) has poor reproducibility between tests and high variability by time of day. In contrast, metabolomic testing of serum has good reproducibility for multiple metabolites, including those altered in GDM. We hypothesize that metabolomics can identify GDM and maintain reproducibility over 3-7 days. STUDY DESIGN: Prospective observational study of women with singleton gestation undergoing GDM screening at 24-28 wks. Two fasting plasma samples were obtained 3-7 days apart. Women were excluded for major medical illness. Exposure groups were defined as glucose tolerant (GT), defined as 1-hour, 50-g glucose challenge test <120mg/dL, and GDM, defined by Carpenter Coustan criteria on a 3-hour, 100-g glucose tolerance test. We determined a priori that 35 subjects per group were needed to detect a mean difference of 1-standard deviation with an alpha of 0.01 and 90% power between GDM and GT. Aqueous extracts of plasma were analyzed by reversephase nanoLC-ESI-MS/MS on a SCIEX 5600 TripleTOF in the ajog.org MEDICAL COMPLICATIONS Oral Concurrent 7
OBJECTIVE: Glucose tolerance testing for gestational diabetes (GDM) has poor reproducibility between tests and high variability by time of day. In contrast, metabolomic testing of serum has good reproducibility for multiple metabolites, including those altered in GDM. We hypothesize that metabolomics can identify GDM and maintain reproducibility over 3-7 days. STUDY DESIGN: Prospective observational study of women with singleton gestation undergoing GDM screening at 24-28 wks. Two fasting plasma samples were obtained 3-7 days apart. Women were excluded for major medical illness. Exposure groups were defined as glucose tolerant (GT), defined as 1-hour, 50-g glucose challenge test <120mg/dL, and GDM, defined by Carpenter Coustan criteria on a 3-hour, 100-g glucose tolerance test. We determined a priori that 35 subjects per group were needed to detect a mean difference of 1-standard deviation with an alpha of 0.01 and 90% power between GDM and GT. Aqueous extracts of plasma were analyzed by reversephase nanoLC-ESI-MS/MS on a SCIEX 5600 TripleTOF in the positive ion mode. Data processing: XCMSonline (peak alignment), MetaboAnalyst (statistics) and Mummichog (pathways). Partial least squared discriminant analysis (PLS-DA) was performed to detect differences in the four groups: GDM visit 1, GDM visit 2, GT visit 1, GT visit 2. RESULTS: Of 65 patients with 2 samples, 30 (46%) had GDM. Women with GDM were significantly more likely to be Hispanic; GT women were mostly black (p<0.01). GDM samples were obtained at a slightly later gestational age (27.5 vs 26.0 wks, p<0.001). Overall, distinct differences were seen between GT and GDM groups. Although there were some variation in metabolomics over a 3-7 day period, several analytes of interest that can be used to distinguish GDM from GT remained stable over a 3-7 day period (Figure 1) . Random forest plots demonstrate the samples separating based on GDM, not visit. Pathway analysis demonstrated differences in ascorbate, amino acid, and glycerophospholipid metabolism between GDM and GT; these pathways were not identified in differences between visits. CONCLUSION: The metabolomics profile at 24-28 wks can distinguish GDM and is reproducible over a 3-7 day period. Further exploration of the specific metabolites and the possibility of using combinations of these metabolites to diagnose GDM should be explored further. 
OBJECTIVE: To evaluate whether real-time continuous glucose monitoring (CGM) improves glycemic control over intermittent self-monitoring of blood glucose (SMBG) in gestational diabetes (GDM). STUDY DESIGN:
This represented a randomized controlled trial at a single academic institution. Patients with GDM were randomized to use either real-time or blinded CGM. The blinded CGM group wore a CGM system that only collected, but did not display data. The realtime CGM group wore a CGM system that collected and displayed continuous glycemic feedback. Both groups also completed SMBG 4-7 times daily. The primary outcome was mean sensor glucose level during the fourth week of CGM use. Secondary outcomes included time spent in and out of a glycemic target of 70-140 mg/dL, polyhydramnios, macrosomia, and a composite of obstetric and neonatal outcomes. Sample size calculations were designed to detect a 20% decrease in mean glucose level with 80% power. RESULTS: From December 2017 through May 2018, a total of 374 patients diagnosed with GDM were referred to our practice. Of these, 40 met inclusion criteria and were enrolled. Twenty patients were randomized into the blinded CGM group and 20 into the realtime CGM group. Twelve (60%) patients in the blinded CGM group and 11 (55%) in the real-time CGM group completed 4 weeks of monitoring and were included in the final analysis. Demographic characteristics were similar between groups. There was no significant difference in mean sensor glucose level between the blinded CGM group (98.9+8.9 mg/dL) and the real-time CGM group (107.5+11.4 mg/dL) in the fourth week of CGM use. There were also no significant differences in time spent in glycemic target, maternal, or neonatal outcomes. An end of participation survey showed that all study patients would consider CGM to monitor glucose in a subsequent pregnancy and all patients in the real-time CGM group believed that the real-time feedback was helpful in managing their GDM. CONCLUSION: Our study showed that the feedback provided by realtime CGM did not significantly decrease mean glucose values compared to SMBG alone after four weeks of CGM use. All patients considered CGM an effective motivational tool for use in GDM.
